[
  {
    "ts": null,
    "headline": "Buy the Dip on This Biotech Stock After Recent Fall",
    "summary": "The biotech stock recently fell from record highs",
    "url": "https://finnhub.io/api/news?id=2a911e4c0b688d4649d9bdbad486b17400e9590efd92f769b9f1032d7d14edb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770666268,
      "headline": "Buy the Dip on This Biotech Stock After Recent Fall",
      "id": 138694770,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The biotech stock recently fell from record highs",
      "url": "https://finnhub.io/api/news?id=2a911e4c0b688d4649d9bdbad486b17400e9590efd92f769b9f1032d7d14edb0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Balances TrumpRx Drug Discounts And HYMPAVZI Review With Valuation Gap",
    "summary": "Pfizer partnered with the U.S. government through TrumpRx to offer deep discounts on more than 30 medications, with the company positioned as the leading participant in the program. The TrumpRx initiative is aimed at lowering out of pocket costs for millions of Americans by improving access to widely used prescription drugs. Separately, the FDA granted Priority Review to Pfizer's supplemental Biologics License Application to expand HYMPAVZI for hemophilia B, including certain pediatric...",
    "url": "https://finnhub.io/api/news?id=e0649f2dbcbaea548ebe57f594bee5d3a30aa1069caed2af6648b40aadb7ee63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770663963,
      "headline": "Pfizer Balances TrumpRx Drug Discounts And HYMPAVZI Review With Valuation Gap",
      "id": 138694771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer partnered with the U.S. government through TrumpRx to offer deep discounts on more than 30 medications, with the company positioned as the leading participant in the program. The TrumpRx initiative is aimed at lowering out of pocket costs for millions of Americans by improving access to widely used prescription drugs. Separately, the FDA granted Priority Review to Pfizer's supplemental Biologics License Application to expand HYMPAVZI for hemophilia B, including certain pediatric...",
      "url": "https://finnhub.io/api/news?id=e0649f2dbcbaea548ebe57f594bee5d3a30aa1069caed2af6648b40aadb7ee63"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend?",
    "summary": "The stock has been fairly stable over the past year.",
    "url": "https://finnhub.io/api/news?id=5894f5a8492c32f32469146d2789e819258736b6cdc6b1e0ae4db23b3fd6ef89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770661200,
      "headline": "Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend?",
      "id": 138693469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The stock has been fairly stable over the past year.",
      "url": "https://finnhub.io/api/news?id=5894f5a8492c32f32469146d2789e819258736b6cdc6b1e0ae4db23b3fd6ef89"
    }
  },
  {
    "ts": null,
    "headline": "BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?",
    "summary": "BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.",
    "url": "https://finnhub.io/api/news?id=d5a61384b04614f81fd439ef3c9e9f187c46cc0736fb314dddc99557548bae90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770650940,
      "headline": "BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?",
      "id": 138609129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.",
      "url": "https://finnhub.io/api/news?id=d5a61384b04614f81fd439ef3c9e9f187c46cc0736fb314dddc99557548bae90"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?",
    "summary": "PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.",
    "url": "https://finnhub.io/api/news?id=6218bf24bf276aa438d0322878a67902e49fbb755d6b459d5558db730538d5d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770646260,
      "headline": "Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?",
      "id": 138514556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.",
      "url": "https://finnhub.io/api/news?id=6218bf24bf276aa438d0322878a67902e49fbb755d6b459d5558db730538d5d7"
    }
  },
  {
    "ts": null,
    "headline": "Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones",
    "summary": "New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (\"Entera\" or the \"Company\"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board",
    "url": "https://finnhub.io/api/news?id=bb3dde604b94c29463b7b822b77dfbd2511a655b9778462a08e93e75195c1e69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770645000,
      "headline": "Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones",
      "id": 138415338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (\"Entera\" or the \"Company\"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board",
      "url": "https://finnhub.io/api/news?id=bb3dde604b94c29463b7b822b77dfbd2511a655b9778462a08e93e75195c1e69"
    }
  },
  {
    "ts": null,
    "headline": "Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?",
    "summary": "MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.",
    "url": "https://finnhub.io/api/news?id=1a35d6254c1cfe8e41d231563a4990b459f3671d7ca8cee14afbfb1a56fe537f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770641460,
      "headline": "Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?",
      "id": 138514993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.",
      "url": "https://finnhub.io/api/news?id=1a35d6254c1cfe8e41d231563a4990b459f3671d7ca8cee14afbfb1a56fe537f"
    }
  },
  {
    "ts": null,
    "headline": "Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea",
    "summary": "Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. David Veitch, Basilea’",
    "url": "https://finnhub.io/api/news?id=88799b6621e0d60ae53659c5810e4b909a6fc6e3f6c5d36b50653061c4a817cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770617700,
      "headline": "Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea",
      "id": 138400005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. David Veitch, Basilea’",
      "url": "https://finnhub.io/api/news?id=88799b6621e0d60ae53659c5810e4b909a6fc6e3f6c5d36b50653061c4a817cf"
    }
  }
]